Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation.

ABSTRACT: Traditional vascular grafts constructed from synthetic polymers or cadaveric human or animal tissues support the clinical need for readily available blood vessels, but often come with associated risks. Histopathological evaluation of these materials has shown adverse host cellular reactions and/or mechanical degradation due to insufficient or inappropriate matrix remodeling. We developed an investigational bioengineered human acellular vessel (HAV), which is currently being studied as a hemodialysis conduit in patients with end-stage renal disease. In rare cases, small samples of HAV were recovered during routine surgical interventions and used to examine the temporal and spatial pattern of the host cell response to the HAV after implantation, from 16 to 200 weeks. We observed a substantia

SUBMITTER: Kirkton RD 

PROVIDER: S-EPMC7557107 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature